Cubist Systematic Strategies’s Madrigal Pharmaceuticals MDGL Stock Holding History

Cubist Systematic Strategies’s Portfolio MDGL Stock Details MDGL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	$3.62M	Buy	7,900 +5,200	+193%	+$1.94M	0.02%	1185
2025 Q2	$817K	Sell	2,700 -500	-16%	-$149K	﹤0.01%	2049
2025 Q1	$1.06M	Hold	3,200	–	–	0.01%	1782
2024 Q4	$987K	Buy	3,200 +1,900	+146%	+$534K	0.01%	1802
2024 Q3	$276K	Buy	+1,300	New	+$333K	﹤0.01%	2458
2024 Q2	–	Sell	-2,200	Closed	-$587K	–	3604
2024 Q1	$587K	Sell	2,200 -400	-15%	-$94.2K	﹤0.01%	2525
2023 Q4	$602K	Buy	+2,600	New	+$455K	﹤0.01%	2427

Other funds holding MDGL

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $30.3B AUM 33.75% 1-Year Est. Return

Cubist Systematic Strategies's MDGL Position: Q3 2025 in Review

Cubist Systematic Strategies opened a new position in Madrigal Pharmaceuticals (MDGL) in Q3 2025: 17,889 shares worth $8.2M. The stake represents 0.04% of the portfolio and ranks #667 among its holdings. This is a return to the name: Cubist Systematic Strategies previously reported a position in MDGL as recently as Q1 2025.

Cubist Systematic Strategies first reported a position in MDGL in Q3 2014 and has held it in 25 quarters since. 352 funds tracked by Wall St. Rank hold MDGL as of Q3 2025.

Cubist Systematic Strategies held 17,889 shares of Madrigal Pharmaceuticals worth $8.2M as of Q3 2025.
Madrigal Pharmaceuticals was a new Cubist Systematic Strategies position in Q3 2025.
Madrigal Pharmaceuticals made up 0.04% of Cubist Systematic Strategies's portfolio in Q3 2025, its #667 holding.
Cubist Systematic Strategies first reported a position in Madrigal Pharmaceuticals in Q3 2014 and has held it in 25 quarters since.
352 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q3 2025.

Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.